Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

Overview of attention for article published in Clinical Cancer Research, July 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

So far, Altmetric has seen 22 X posts from 16 X users, with an upper bound of 76,682 followers.

New article: Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. https://t.co/cT1qGmOjpi #gastriccancer #oncology https://t.co/NyBIXkROyP

RT @CCR_AACR: In the July issue: Phase II Trial: Nintedanib in gastric cancer. https://t.co/gAVUTuf9p4 https://t.co/Eu20j8bj9l

In the July issue: Phase II Trial: Nintedanib in gastric cancer. https://t.co/gAVUTuf9p4 https://t.co/Eu20j8bj9l

Efficacy of Combined VEGFR1-3, PDGF{alpha}/{beta}, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer https://t.co/TnEpP3Epv1

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 18 additional X posts.